OR4A16

Across TCGA pan-cancer cohorts, OR4A16 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR4A16 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher OR4A16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR4A16 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, LUSC, and LIHC are the cancer types where OR4A16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
LUSC	OS	Median	All	0.121	0.824	<.001	18	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	8	view →
LGG	OS	Median	All	0.306	0.799	.009	3	view →
SKCM	OS	Median	IV	0.179	0.727	<.001	3	view →
UCEC	DFS	Median	All	0.967	0.830	.042	2	view →
COAD	OS	Median	All	0.598	0.873	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR4A16–ESCA (OS)

Open the ESCA breakdown →